Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/26498 |
Resumo: | Introduction: Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST-T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone. |
id |
UNIFEI_4a069dc9113ce3b863c54121d9a7483b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/26498 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusionEspirololactona y eplerenona son cardioprotectoras durante la fase temprana de isquemia em ratas sometidas a oclusión coronária agudaEspironolactona e eplerenona são cardioprotetoras durante a fase precoce de isquemia em ratos submetidos à oclusão coronária Infarto agudo do miocárdioECGEspironolactonaEplerenonaCardioprotetor. Acute myocardial infarctionECGSpironolactoneEplerenoneCardioprotective. ECGInfarto agudo de miocárdioEspironolactonaEplerenonaCardioprotector.Introduction: Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST-T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone. Introducción: Los antagonistas de los receptores de mineralocorticoides (MRA) son efectivos para reducir el remodelado del ventrículo izquierdo y la muerte súbita tras un infarto agudo de miocardio (IAM). Objetivo: Los MRA in vitro tienen efectos cardioprotectores, independientes de la MR; sin embargo, no se sabe si los efectos rápidos de los MRA son cardioprotectores in vivo. Este estudio evaluó los efectos agudos de la espironolactona y la eplerenona en los primeros minutos del IAM. Métodos: Ratas Wistar, sometidas o no a adrenalectomía bilateral, fueron tratadas por vía oral con espironolactona (20 mg/kg) o eplerenona (10 mg/kg), y sometidas a ligadura de la arteria coronaria izquierda, bajo anestesia. Se obtuvieron registros de electrocardiograma (ECG) para evaluar el segmento ST-T, el intervalo QT y los intervalos QTc. También se midió la presión arterial antes (línea de base) y después de la ligadura coronaria. Resultados: La espironolactona o la eplerenona administradas una hora antes de la ligadura coronaria previnieron la elevación del segmento ST-T en pacientes adrenalectomizados y no adrenalectomizados. El análisis del intervalo QT mostró que los MRA evitaban su prolongación después de la ligadura coronaria. Los intervalos QT y QTc se mantuvieron similares a los basales y fueron inferiores a los valores exhibidos por el grupo no tratado. Los animales tratados con espironolactona, independientemente de la adrenalectomía, tuvieron tasas de mortalidad 3 veces más bajas en comparación con el grupo de control. Conclusión: Los MRA tienen efectos cardioprotectores agudos en la fase inicial del IAM, que son independientes de la aldosterona.Introdução: Os antagonistas do receptor de mineralocorticóide (MRAs) são eficazes na redução da remodelação do ventrículo esquerdo e morte súbita após infarto agudo do miocárdio (IAM). Objetivo: MRAs in vitro apresentam efeitos cardioprotetores, independente do MR; no entanto, não se sabe se os efeitos rápidos dos MRAs são cardioprotetores in vivo. Este estudo avaliou os efeitos agudos da espironolactona e da eplerenona nos primeiros minutos do IAM. Métodos: Ratos Wistar, submetidos ou não à adrenalectomia bilateral, foram tratados por via oral com espironolactona (20 mg / kg) ou eplerenona (10 mg / kg), e submetidos à ligadura da coronária esquerda, sob anestesia. Registros de eletrocardiograma (ECG) foram obtidos para avaliar o segmento ST-T, o intervalo QT e os intervalos QTc. A pressão arterial também foi medida antes (linha de base) e após a ligadura coronária. Resultados: Espironolactona ou eplerenona administrada uma hora antes da ligadura coronária preveniu a elevação do segmento ST-T em adrenalectomizados e não adrenalectomizados. A análise do intervalo QT mostrou que os MRAs impediram seu prolongamento após a ligadura coronária. Os intervalos QT e QTc permaneceram semelhantes à linha de base e foram menores do que os valores exibidos pelo grupo não tratado. Os animais tratados com espironolactona, independentemente da adrenalectomia, apresentaram taxas de mortalidade 3 vezes menores em comparação com o grupo controle. Conclusão: Os MRAs apresentam efeitos cardioprotetores agudos na fase inicial do IAM, que são independentes da aldosterona.Research, Society and Development2022-02-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2649810.33448/rsd-v11i3.26498Research, Society and Development; Vol. 11 No. 3; e24011326498Research, Society and Development; Vol. 11 Núm. 3; e24011326498Research, Society and Development; v. 11 n. 3; e240113264982525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/26498/23200Copyright (c) 2022 Gabriela de Cássia Sousa Amancio; Milla Marques Hermidorff; Ana Cláudia Alvarenga; Wanderson Geraldo Lima; Homero Nogueira Guimarães; Henrique Resende Rodrigues; Emília Calil Silva; Leonardo Vinícius Monteiro de Assis; Andrea Grabe-Guimarães; Mauro Cesar Isoldihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAmancio, Gabriela de Cássia Sousa Hermidorff, Milla MarquesAlvarenga, Ana Cláudia Lima, Wanderson GeraldoGuimarães, Homero Nogueira Rodrigues, Henrique ResendeSilva, Emília Calil Assis, Leonardo Vinícius Monteiro deGrabe-Guimarães, Andrea Isoldi, Mauro Cesar2022-03-09T13:44:38Zoai:ojs.pkp.sfu.ca:article/26498Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:44:31.707221Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion Espirololactona y eplerenona son cardioprotectoras durante la fase temprana de isquemia em ratas sometidas a oclusión coronária aguda Espironolactona e eplerenona são cardioprotetoras durante a fase precoce de isquemia em ratos submetidos à oclusão coronária |
title |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
spellingShingle |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion Amancio, Gabriela de Cássia Sousa Infarto agudo do miocárdio ECG Espironolactona Eplerenona Cardioprotetor. Acute myocardial infarction ECG Spironolactone Eplerenone Cardioprotective. ECG Infarto agudo de miocárdio Espironolactona Eplerenona Cardioprotector. |
title_short |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
title_full |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
title_fullStr |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
title_full_unstemmed |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
title_sort |
Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion |
author |
Amancio, Gabriela de Cássia Sousa |
author_facet |
Amancio, Gabriela de Cássia Sousa Hermidorff, Milla Marques Alvarenga, Ana Cláudia Lima, Wanderson Geraldo Guimarães, Homero Nogueira Rodrigues, Henrique Resende Silva, Emília Calil Assis, Leonardo Vinícius Monteiro de Grabe-Guimarães, Andrea Isoldi, Mauro Cesar |
author_role |
author |
author2 |
Hermidorff, Milla Marques Alvarenga, Ana Cláudia Lima, Wanderson Geraldo Guimarães, Homero Nogueira Rodrigues, Henrique Resende Silva, Emília Calil Assis, Leonardo Vinícius Monteiro de Grabe-Guimarães, Andrea Isoldi, Mauro Cesar |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Amancio, Gabriela de Cássia Sousa Hermidorff, Milla Marques Alvarenga, Ana Cláudia Lima, Wanderson Geraldo Guimarães, Homero Nogueira Rodrigues, Henrique Resende Silva, Emília Calil Assis, Leonardo Vinícius Monteiro de Grabe-Guimarães, Andrea Isoldi, Mauro Cesar |
dc.subject.por.fl_str_mv |
Infarto agudo do miocárdio ECG Espironolactona Eplerenona Cardioprotetor. Acute myocardial infarction ECG Spironolactone Eplerenone Cardioprotective. ECG Infarto agudo de miocárdio Espironolactona Eplerenona Cardioprotector. |
topic |
Infarto agudo do miocárdio ECG Espironolactona Eplerenona Cardioprotetor. Acute myocardial infarction ECG Spironolactone Eplerenone Cardioprotective. ECG Infarto agudo de miocárdio Espironolactona Eplerenona Cardioprotector. |
description |
Introduction: Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST-T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-02-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/26498 10.33448/rsd-v11i3.26498 |
url |
https://rsdjournal.org/index.php/rsd/article/view/26498 |
identifier_str_mv |
10.33448/rsd-v11i3.26498 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/26498/23200 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 3; e24011326498 Research, Society and Development; Vol. 11 Núm. 3; e24011326498 Research, Society and Development; v. 11 n. 3; e24011326498 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052810997530624 |